Asian Spectator


The Times

.

Mangroves Documentary Premieres, Exploring How Cities and Wetlands Coexist

SHENZHEN, CHINA – Media OutReach Newswire – 17 November 2026 – Guangdong Radio and Television has unveiled Mangroves, a three-part ecological documentary filmed in 4K ultra-high de...

Together, Restart from Heart Tithe Ethical Consumption Movement 2022 Shopping Rewards Scheme, Pop-up Store, Workshop Support social enterprise with consumption

HONG KONG SAR - Media OutReach - 3 November 2022 - The 11th Tithe Ethical Consumption Movement (TECM) organised by the Fullness Social Enterprises Society (FSES) is themed with "Together, R...

Cutting-edge products and latest tech to go on show in Shenzhen

SHENZHEN, China, Nov. 15, 2019 /PRNewswire-AsiaNet/ -- - 70+: the number of launches of new technologies and products at the China Hi-Tech Fair 2019 -Among the highlights of the China Hi-Tec...

Chinachem Volunteers make a companion with 100 kids Enjoy “Toy story 4” movie and Lunch buffet in summer

HONG KONG, CHINA - Media OutReach - 29 July 2019 - In collaboration with S.K.H. St. Christopher's Home, Chinachem Volunteer Team has just spread loves to 100 kids th...

Trina Solar Launches New Smart PV Solution - TrinaPro

CHANGZHOU, China, March 23, 2018 /PRNewswire-AsiaNet/ -- On March 21, 2018, Trina Solar Limited ("Trina Solar" or the "Company"), a leading total solutions provider for solar energy, launche...

Jacobson Pharma Announces FY2021 Annual Results

HONG KONG, Jun 29, 2021 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in the research, developmen...

Forest City SFZ Clarifies Incentive Framework for Fintech and AI-Enabled Financial Services Alongside Malaysia Digital Incentives

Forest City SFZ sets out who may qualify for its 5% special corporate tax rate, how the separate Malaysia Digital tax incentive works, and which activities and conditions apply to each schem...

Priced at 800,000 RMB, Human Horizons HiPhi X is Setting New S...

SHANGHAI, Sept. 6, 2021 /PRNewswire-AsiaNet/ -- Priced at RMB 800,000, the HiPhi X 4-seater was unveiled to customers during the Chengdu Motor Show (Hall 10 Booth H1002). Designed and manufa...

The Decision of the German Federal Court of Justice Confirms T...

PARIS, Feb. 13, 2019 /PRNewswire-AsiaNet/ -- Echosens announced today that the company has received a favorable ruling from the internationally highly esteemed German Federal Court of Justic...

Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China

Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China

TOKYO, Feb 25, 2020 - (JCN Newswire) - Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced today that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN, for development and distribution in China.

Based on this agreement, Eisai will acquire exclusive development and marketing rights for dotinurad in China from FUJI YAKUHIN. FUJI YAKUHIN will retain responsibility for manufacturing the formulation of dotinurad, and supply to Eisai. Eisai will be responsible for a New Drug Application for dotinurad in China and pay FUJI YAKUHIN upfront payment, development milestone and sales milestone.

Hyperuricemia is the second most common metabolic disease after diabetes mellitus in China. In addition, hyperuricemia is known to be associated with various diseases in the urinary system, endocrine system, metabolic system, cardio-cerebrovascular system etc., including gout.

Furthermore, it is estimated that currently in China, the number of patients with hyperuricemia is approximately 190 million and the number of patients with gout is approximately 16 million.(1) It is expected that the number of patients will further increase in the near future due to changes in lifestyle and dietary preferences in accordance with socio-economic development in China.

Dotinurad is a new therapeutic agent for gout and hyperuricemia discovered by FUJI YAKUHIN. Dotinurad suppresses uric acid reabsorption and lowers blood uric acid levels, by selectively inhibiting the urate transporter (URAT1) related to reabsorption of uric acid in the kidney.

Under this agreement, Eisai will proceed with the development of dotinurad in China. Following commercialization, Eisai will aim to contribute to patients with hyperuricemia that are unmet medical needs by utilizing the knowledge and networks that Eisai has cultivated through its China business. FUJI YAKUHIN anticipates maximizing the value of dotinurad in China by leveraging Eisai's business base as the first step in the global expansion of dotinurad. Through the development and commercialization of dotinurad, Eisai and FUJI YAKUHIN will provide new treatment options for hyperuricemia and gout in China and contribute to improving the quality of life of patients.

About Eisai Co., Ltd.

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.

As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For further information on Eisai Co., Ltd., please visit https://www.eisai.com.

About FUJI YAKUHIN CO., LTD.

FUJI YAKUHIN CO., LTD. is a complex pharmaceutical company with an integrated manufacturing and sales system consisting of ethical drug sales, placement drug sales, drugstore business, and the pharmaceutical manufacturing business that supports them. Regarding ethical drugs, FUJI YAKUHIN has created two drugs with different mechanisms of action, topiroxostat and dotinurad, for gout and hyperuricemia.

For further information on FUJI YAKUHIN CO., LTD., please visit https://www.fujiyakuhin.co.jp/ (Japanese only)

About dotinurad

URAT1 and has a small effect on other transporters, so it reduces serum uric acid levels at lower doses. Dotinurad is expected to have a low risk of side effects and drug interaction.In Japan, on January 23, 2020, FUJI YAKUHIN CO., LTD. obtained manufacturing and marketing approval for dotinurad.

References:(1) For the estimated data regarding the number of patients with hyperuricemia as well as the number of patients with gout:- Dataofmorbidityprevalencerate-RuiLiuetal., PrevalenceofHyperuricemiaandGoutinMainlandChinafrom2000to2014: A Systematic Review and Meta-Analysis, BioMed Research International, Volume 2015, Article ID 762820- Estimated data calculated from United Nations World Population Estimates - World Population Prospects, URL: http://www.un.org/en/development/desa/population/

Contact:Eisai Co., Ltd.
Public Relations Department 
TEL: +81-(0)3-3817-5120

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegaluk casinos not on gamstophttps://www.capitolcitycinema.org/grandpashabet girisStreamEastStreamEastjojobet